Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

American Journal of Psychiatry

Volumn 162, Issue 5, 2005, Pages 1010-1012

  Knegtering, Rikus ^a,b   Baselmans, Pepijn ^a   Castelein, Stynke ^a   Bosker, Fokko ^a   Bruggeman, Richard ^a   Van Den Bosch, Robert J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DRUG METABOLITE; OLANZAPINE; PALIPERIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG EFFECT; DRUG METABOLISM; FEMALE; HUMAN; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERPROLACTINEMIA; ISOXAZOLES; MALE; MIDDLE AGED; PROLACTIN; PSYCHOTIC DISORDERS; PYRIMIDINES; RISPERIDONE;

EID: 18744408824     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.5.1010     Document Type: Article

References (12)

1. Kapur S, Langois X, Vinken P, Megens AA, Coster de R, Andrews JS: The differential effects of atypical anti-psychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002; 302:1129-1134
2. Leysen JE: Review of neuroleptic receptors: specificity and multiplicity of in vitro binding related to pharmacological activity in clinical pharmacology, in Psychiatry: Neuroleptic and Antidepressant Research. Edited by Usdin E, Dahl SG, Gram LF, Lingjaerde O. London, Macmillan, 1981, pp 35-62
3. Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA: In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992; 41:494-508
4. Knegtering H, Lamberts PA, Prakken G, ten Brink C: Serum prolactin levels and sexual dysfunction in antipsychotic medication, such as risperidone: a review. Acta Neuropsychiatrica 2000; 12:19-26
5. 2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001; 158:311-314
6. van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldermans WE, Heykants JJ: Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 1994; 114:53-62
7. Aravagiri M, Yuwiler A, Marder SR: Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl) 1998; 139:346-363
8. Turrone P, Kapur S, Seeman MV, Flint AJ: Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159: 133-135
9. Bowden CR, Viona SJ, Woestenborghs R, de Coster R, Heykants J: Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. J Pharmacol Exp Ther 1992; 262:699-706
10. Mannens G, Meuldermans W, Snoeck E, Heykants J: Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl) 1994; 144:566-572
11. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, van Beijsterveldt LE, van Peer A, Woestenborghs R: The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55(suppl):13-17
12. Knegtering H, van der Moolen AEGM, Castelein S, Kluiter H, van den Bosch RJ: What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003; 22(suppl 2):109-123